At present, NT-proBNP is a crucial element of risk stratification in PAH patients and is addressed in both the risk score developed from the REVEAL registry (Registry to Evaluate Early and Long-Term PAH Disease Management) [9,10] and in the risk stratification method proposed by ESC/ERS guidelines [2]. This evidence concerns the gene NPPB and pulmonary arterial hypertension.